Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 425-400-6 | CAS number: 179986-09-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 008
- Report date:
- 2008
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.26 (Sub-Chronic Oral Toxicity Test: Repeated Dose 90-Day Oral Toxicity Study in Rodents)
- Principles of method if other than guideline:
- To reduce the number of animals, it was decided to combine a 90-day toxicity study (Part A) with a one-generation study (Part B) performed simultaneously with the same test item and dose levels at NOTOX. This was done by using the male animals exposed for ten weeks during the 90-day toxicity study for mating with the female animals exposed for two weeks at the same dose level during the one-generation study.
The treatment period for the males and females of the 90-day toxicity study was at least 13 weeks continuously. The treatment period for the females of the one-generation study was at least 8 weeks continuously.
For the 90-day toxicity study 48 male rats and 40 female rats were used; for the one-generation study 96 female rats were used.
On request of the UK authorities, the following was added:
Semen analysis (sperm motility, count and morphology)
Staging of spermatogenesis (detailed histopathology of the testes)
Oestrus cycle monitoring - GLP compliance:
- yes
Test material
- Reference substance name:
- -
- EC Number:
- 425-400-6
- EC Name:
- -
- Cas Number:
- 179986-09-5
- Molecular formula:
- UVCB substance
- IUPAC Name:
- methyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propanoate; propane-1,2,3-triol; tetradecanoic acid
- Details on test material:
- - Physical state: colourless paste
- Analytical purity: not indicated by the sponsor; treated as 100% pure
- Storage condition of test material: at room temperature protected from light
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Deutschland, Sulzfeld, Germany
- Age at study initiation: 6 weeks
- Weight at study initiation: males 175-177 g, females 133-138 g
- Housing: Males were housed in groups of 5 males/cage in Macrolon cages. The additional males were housed in groups of 2 males/cage in Macrolon cages. Females were housed in groups of 5 females/cage in Macrolon cages.
- Diet (ad libitum): pelleted rodent diet (SM R/M-Z from SSNIFF® SpeziaIdiaten GmbH, Soest, Germany)
- Water (ad libitum): tap water
- Acclimation period: 7 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21 +/- 3
- Humidity (%): 30-70
- Air changes (per hr): 15
- Photoperiod (hrs dark / hrs light): 12/12
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- polyethylene glycol
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS
daily, 2 hours prior to dosing
VEHICLE
- Concentration in vehicle: 5, 10, 20 mg/ml
- Amount of vehicle (if gavage): 2 ml/kg bw
- Lot/batch no. (if required): 17644FC6 - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Quantitative analysis was based on the analytical method validated for the test substance in NOTOX project 487737.
- Duration of treatment / exposure:
- 90 days
- Frequency of treatment:
- daily
Doses / concentrations
- Remarks:
- Doses / Concentrations:
14, 56, 222 mg/kg bw/day
Basis:
actual ingested
- No. of animals per sex per dose:
- 12 males, 10 females
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: The dose levels were based on the results of a 28-day toxicity study (RCC Project 636456).
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: at least twice daily
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: daily
BODY WEIGHT: Yes
- Time schedule for examinations: weekly
FOOD CONSUMPTION: Yes
- Time schedule for examinations: weekly
OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: at begin and end of the study
- Dose groups that were examined: all groups
HAEMATOLOGY: Yes
- Time schedule for collection of blood: on the day of necropsy
- Anaesthetic used for blood collection: Yes (isoflurane)
- Animals fasted: Yes
- How many animals: all surviving animals
- Parameters checked: white blood cells, differential leucocyte count (neutrophils, lymphocytes, monocytes, eosinophils, basophils), red blood cells, reticulocytes, red blood cell distribution width, haemoglobin, haematocrit, mean corpuscular volume, mean corpuscular haemoglobin, mean corpuscular haemoglobin concentration, platelets, prothrombin time, activated partial thromboplastin time
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: on the day of necropsy
- Animals fasted: Yes
- How many animals: all surviving animals
- Parameters checked: alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total protein, albumin, total bilirubin, urea, creatinine, glucose, cholesterol, sodium, potassium, chloride, calcium, inorganic phosphate
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: at the end of the treatment
- Dose groups that were examined: all animals
- Battery of functions tested: hearing ability, pupillary reflex, static righting reflex and grip strength - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: Yes - Other examinations:
- On request of the UK authorities, the following was added:
- Semen analysis (sperm motility, count and morphology)
- Staging of spermatogenesis (detailed histopathology of the testes)
- Oestrus cycle monitoring - Statistics:
- The following statistical methods were used to analyse the data:
- lf the variables could be assumed to follow a normal distribution, the Dunnett-test (many-to-one t-test) based on a pooled variance estimate was applied for the comparison of the treated groups and the control groups for each sex.
- The Steel-test (many-to-one ranktest) was applied if the data could not be assumed to follow a normal distribution.
- The Fisher Exact-test was applied to frequency data.
- The T-test was applied for testis and epididymidis concentrations.
- The percentage of motile spermatozoa, progressive motile spermatozoa and sperm with normal morphology was subjected to the Kruskal-Wallis nonparametric ANOVA test to determine intergroup difference. Ifthe results ofthe ANOVA were significant (p<0.05), the Wilcoxon test was applied to the data to compare the treated groups to the control group.
AII tests were two-sided and in all cases p < 0.05 was accepted as the lowest level of significance.
No statistical analysis was performed on histopathology findings.
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- There were no clinical signs of toxicity noted during the observation period, except salivation and incidental findings (e.g. alopecia, wounds, broken tails).
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- There were no clinical signs of toxicity noted during the observation period, except salivation and incidental findings (e.g. alopecia, wounds, broken tails).
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- Food consumption of treated animals remained in the same range as controls over the study period.
- Ophthalmological findings:
- no effects observed
- Description (incidence and severity):
- No treatment related effects were noted at ophthalmoscopic examination up to 222 mg/kg body weight/day.
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Slightly reduced values for prothrombin time were noted for males and females treated at 56 and 222 mg/kg bw/day.
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- At 222 mg/kg, slight increased values for total protein, albumin and total bilirubin were observed for males and females. Additionally at this dose, females showed a decreased glucose level.
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- no effects observed
- Description (incidence and severity):
- No changes were observed in hearing ability, pupillary reflex, static righting reflex and grip strength in the treated animals when compared to control animals. A variation in motor activity did not indicate a relation with treatment.
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- at 56 and 222 mg/kg bw/day (see deteails)
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- At 222 and 56 mg/kg bw hepatic changes (enlarged and discolorated livers) in males and females were observed (see details).
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Treatment related changes were present in the liver (periacinar hepatocytic hypertrophy) and thyroid (follicular epithelial hypertrophy) noted in males and females treated at 56 and 222 mg/kg bw (see details).
- Histopathological findings: neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Thyroid follicular adenoma was noted for one male of the 222 mg/kg bw dose group.
- Details on results:
- CLINICAL SIGNS AND MORTALITY
There were no clinical signs of toxicity noted during the observation period.
Salivation was noted in all males treated at 56 and 222 mg/kg and to a lesser extent in males treated at 14 mg/kg. Salivation was noted at least once in one female treated at 14 mg/kg, in all females treated at 56 mg/kg and was repeatedly noted in all females treated at 222 mg/kg. Salivation was considered to be a physiological response to the taste of the formulation rather than a sign of systemic toxicity, considering the nature, minor severity of the effect and its time of occurrence (i.e. after dosing). Therefore, this was considered not toxicologically relevant. Incidental findings that were noted included alopecia, scabs and wound at several body parts, broken tail apex, broken upper incisors, and rales. These findings are commonly noted in rats of this age and strain which are housed and treated under the conditions in this study. At the incidence observed, these were considered signs of no toxicological significance.
BODY WEIGHT AND WEIGHT GAIN
Body weights and body weight gain of treated animals remained in the same range as controls over the study period.
FOOD CONSUMPTION AND COMPOUND INTAKE
Food consumption (absolute and relative) of treated animals remained in the same range as controls over the study period.
OPHTHALMOSCOPIC EXAMINATION
No treatment related effects were noted at ophthalmoscopic examination up to 222 mg/kg bw.
HAEMATOLOGY
Slightly reduced values for prothrombin time were noted for males and females treated at 56 and 222 mg/kg body weight/day.
AII other statistical significant changes were not considered to be due to treatment as no dose response relationship was noted, the values were within normal limits, the control values were at the upper/lower end of the normal range and/or no corroborative findings were noted.
Individual increases of neutrophil counts with concurrently reduced lymphocyte counts were noted for one high dose male and two low dose females.
This shift in type of white blood cells was considered to be a secondary non-specific response to stress and to be of no toxicological significance. At scheduled necropsy, all three animals showed reddish or red-brown discolouration of the thymus.
CLINICAL CHEMISTRY
At 222 mg/kg, slight increased values for total protein, albumin and total bilirubin were observed for males (5, 3 and 20%) and females (8, 5, 37%). Additionally at this dose, females showed a decreased glucose level (about 20 %). AII other statistical significant changes were not considered to be due to treatment as no dose response relationship was noted, the values were within normal limits, the control values were at the upper/lower end of the normal range and/or no corroborative findings were noted.
ORGAN WEIGHTS
Organ weight changes were noted at 56 and 222 mg/kg for both sexes. These changes consisted at 222 mg/kg bw of increased liver weights for males (about 40%) and females (about 46%) and increased thyroids weights both sexes (80% for males, 46 % for females).
Mid and high dose males showed increased kidneys and prostate weights (absolute and relative). As these values were within normal limits and no microscopic correlate was observed, these changes were considered not toxicologically significant.
AII other statistical significant changes were not considered treatment-related as no dose response relationship was noted.
GROSS PATHOLOGY
At 222 mg/kg, hepatic changes were noted. These consisted of accentuated lobular pattern (one male and one female), enlarged livers (seven males), black-brown or red-brown discoloration (five males and nine females) and thickened and dark-red discoloured papillary process (one female). To a lesser extent hepatic abnormalities were seen in animals treated at 56 mg/kg/day (one male showed an enlarged liver and two females showed black-brown discolouration).
One control male showed the left testes and epididymidis reduced in size. During in-life this was noted as undescended left testicle.Incidental findings included bent tail apex, nodules on and enlargement of the preputial glands, alopecia and scab formation of the skin, reduced seminal vesicles size, discoloration of the adrenals and the lymph node (mandibular), reduced size of papillary process of the liver, foci on the lungs, and discoloration and foci on the thymus. These findings are occasionally seen among rats used in these types of study and in the absence of correlated microscopic findings they were not considered changes of toxicological significance.
Some females from each dose group were found with watery fluid in the uterus; this is related to a stage in the oestrous cycle and constitutes a normal finding.
HISTOPATHOLOGY: NON-NEOPLASTIC
Treatment related changes were present in the liver (periacinar hepatocytic hypertrophy) and thyroid (follicular epithelial hypertrophy) noted in males and females treated at 56 and 222 mg/kg bw.
Periacinar hepatocytic hypertrophy was seen in six males and six females treated at 56 mg/kg and in all animals treated at 222 mg/kg. Thyroid follicular epithelial hypertrophy was observed for eight males/two females of the 56 mg/kg bw dose group and nine males/five females of the 222 mg/kg bw dose group.
The hypertrophic changes in liver and thyroid were both treatment and dosage related changes.
The hepatic enlargement and accentuated lobular pattern recorded at necropsy are gross correlates of periacinar hepatocytic hypertrophy. There was no microscopic evidence of pigmentation to correlate with gross discolouration.
Other findings were usual occurrences in laboratory rats and none were related to treatment.
HISTOPATHOLOGY: NEOPLASTIC
Thyroid follicular adenoma was noted for one male of the 222 mg/kg bw dose group.
OTHER FINDINGS
Sperm examination: At all dose levels, decreased sperm motility and progressive motility was noted (at 222 mg/kg bw: 20 resp. 40%). The concurrent control was right at the historical control mean. The values of the treated groups were at the lower end of the historical control range.
The number of testicular and epididymidal sperm cells and the percentage of normal sperm cells was similar for the 222 mg/kg bw dose group and control group.
Left testis weight was statistically significantly increased in the animals of the 222 mg/kg bw dose group (about 12%). These values were considered to be within normal limits and as this effect was not observed for the total testes weight it was not considered toxicologically relevant.
In the testes sections which were stained PAS/haematoxylin, in addition to sections stained H&E, no variation was present in the staging of spermatogenesis between the 222 mg/kg bw treated and the control group.
Effect levels
- Dose descriptor:
- NOAEL
- Effect level:
- 14 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: hepatic and thyroidal changes
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
Summary tables are given in the attachments
Tables 1 Absolute organ weights males
Table 2 Relative organ weights males
Table 3 Absolute organ weights females
Table 4 Relative organ weights females
Table 5: Macroscopic findings summary
Table 6: Incidence of histopathology findings for liver, kidney and thyroid, males
Table 7: Incidence of histopathology findings for liver and thyroid, females
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.